Modality
mAb
MOA
DLL3 ADC
Target
JAK2
Pathway
Complement
Gastric CaPancreatic CaHNSCC
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
Jan 2024
→ Jan 2028
Phase 1Current
NCT05263865
139 pts·Pancreatic Ca
2024-01→2028-01·Recruiting
139 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-091.8y awayPh2 Data· Pancreatic Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Recruit…
Catalysts
Ph2 Data
2028-01-09 · 1.8y away
Pancreatic Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05263865 | Phase 1/2 | Pancreatic Ca | Recruiting | 139 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |